To investigate the prognostic value of PD ‐L1 expression combined with CD 8 + TIL s density in patients with resected NSCLC and correlations with clinicopathological features. We retrospectively enrolled 178 patients with resected NSCLC from 2011 to 2015. All surgical primary and 58 matched metastatic lymph node specimens were tested for PD ‐L1, CD 8 + TIL s, and oncogenic alterations. PD ‐L1 + was detected in 71 (39.9%) and CD 8 high TIL s in 74 (41.6%) cases. Smoking, Sq CC , and EGFR − were associated with both PD ‐L1 + and CD 8 high TIL s. Patients with CD 8 high TIL s had longer OS ( P = 0.012). PD ‐L1 − was significantly associated with longer OS in patients with oncogenic alterations ( P = 0.047). By multivariate analysis, CD 8 high TIL s ( HR = 0.411; 95% CI , 0.177–0.954; P = 0.038), rather than PD ‐L1, was the independent predictive factor for OS . The longest and shortest OS were achieved in patients with PD ‐L1 + / CD 8 high and PD ‐L1 + / CD 8 low , respectively ( P = 0.025). Inconsistent PD ‐L1 expression levels were observed in 23 of 58 (39.7%) patients with primary and matched metastatic lymph node specimens. Of them, CD 8 high TIL s was significantly associated with longer OS in patients with metastatic lymph nodes and/or consistent PD ‐L1 expression ( P = 0.017 and 0.049, respectively). The combination of PD ‐L1 and CD 8 + TIL s density, instead of PD ‐L1 alone, suggested impressive prognostic values in NSCLC patients. Less than half of patients with resected NSCLC experienced inconsistent PD ‐L1 expression between primary and metastatic lesions. The level of PD ‐L1 expression in advanced NSCLC needs to be evaluated more comprehensively.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: